How to choose subsequent treatment options after evantumumab resistance

Amivantamab is a therapeutic drug for EGFR mutation-positive non-small cell lung cancer (NSCLC). It is especially suitable for patients who are resistant to other EGFR inhibitors (such as osimertinib, gefitinib, etc.). Although evantumumab shows significant efficacy in many patients, resistance may develop in some patients over time. Therefore, the treatment plan after drug resistance needs to be individually adjusted according to the patient's drug resistance mechanism and changes in the condition.

When evantumumab is resistant, genetic testing is first needed to clarify the resistance mechanism. Common resistance mechanisms includeEGFR gene mutations (such as T790M mutation), MET gene amplification, or other unknown molecular mechanisms. In these cases, doctors can choose different treatment strategies for different resistance mechanisms. For example, if resistance is related to MET amplification, MET inhibitors such as crizotinib can become an effective option for subsequent treatment. For patients with positive T790M mutations, other new generation EGFR inhibitors, such as osimertinib, can be considered, or used in combination with other drugs in order to improve the efficacy.

For some specific patients, immunotherapy is also an important option. PD-1/PD-L1 inhibitors, such as Pembrolizumab or Nivolumab, are widely used in immunotherapy for non-small cell lung cancer, especially for patients who still have no effective treatment options after EGFR mutation or MET amplification. These immunotherapy drugs effectively delay cancer progression by activating the patient's immune system and enhancing its recognition and attack of cancer cells.

In addition, chemotherapy, as a traditional treatment method, is still one of the subsequent treatment options for some patients. Although chemotherapy may not be able to attack tumor cells as specifically as targeted therapy, in some cases, especially when other targeted drugs and immunotherapy are ineffective, chemotherapy can still play a better therapeutic role.

Reference materials:https://www.rybrevant.com/